Ressourcen

Dieser Abschnitt enthält internationale Forschungsergebnisse und kann auf Indikationen verweisen, die nicht in allen Regionen zugelassen sind. Bitte konsultieren Sie vor der Anwendung die lokal zugelassenen Indikationen.

Filtern nach:

Suche
RAMAT GAN, Israel, Nov. 3, 2025 /PRNewswire/ -- Pulsenmore Ltd. (TASE: PULS), a pioneer in home ultrasound solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted
Innovation happens when clinicians and technology come together.
Stop by the GE HealthCare booth to experience Pulsenmore
Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel's largest HMO. Over the next
Pulsenmore secured a commercial agreement with Sheba Medical Center, Tel Hashomer for remote patient monitoring of highrisk pregnancies using its’ home ultrasound solution. Sheba Medical Center, will utilize Pulsenmore's solution
Pulsenmore (TASE:PULS), the world leader in self-scan ultrasound technology for at-home use and remote clinical diagnosis, announces its new clinical study collaboration with Michigan Medicine. The study will examine the

Am Puls der Zeit bleiben

Wir laden Sie ein, sich für unseren vierteljährlich erscheinenden Newsletter zu registrieren, um auf dem Laufenden zu bleiben

Häufig gestellte Fragen

Häufig gestellte Fragen